Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$462.00K$462.00K−77.5% vs Q1 2016 Net Income-$6.98M-$6.98MN/M vs Q1 2016 EPS Diluted-$0.60-$0.60N/M vs Q1 2016 Operating Income-$6,939,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,227,000N/M Margins · derivedOperating margin-1501.9%−1368.5 pt vs Q1 2016
Net margin-1510.8%−1376.3 pt vs Q1 2016
ended Mar 31, 2017 · filed May 11, 2017 · 41 d after period end